華納藥廠(688799.SH):子公司通過藥品 GMP 符合性檢查
格隆匯2月16日丨華納藥廠(688799.SH)公佈,近日,公司全資子公司湖南華納大藥廠手性藥物有限公司(以下簡稱"手性藥物公司")收到湖南省藥品監督管理局簽發的《藥品 GMP 符合性檢查吿知書》,其位於長沙市望城區的異丙託溴銨、二甲硅油等 2 個原料藥品種已通過藥品生產質量規範符合性檢查(即藥品GMP 符合性檢查)。
本次通過藥品 GMP 符合性檢查,標誌着手性藥物公司可以正式生產和銷售上述原料藥產品,上述藥品通過 GMP 符合性檢查不會對公司近期業績產生重大影響。由於藥品的生產、銷售受市場環境變化等因素影響,存在不確定性,敬請廣大投資者謹慎決策,注意防範投資風險。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.